DOCSLIB.ORG

Nucleotide Excision Repair Gene Polymorphisms and Recurrence After Treatment for Superficial Bladder Cancer

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Nucleotide Excision Repair Gene Polymorphisms and Recurrence After Treatment for Superficial Bladder Cancer 1408 Vol. 11, 1408–1415, February 15, 2005 Clinical Cancer Research Nucleotide Excision Repair Gene Polymorphisms and Recurrence after Treatment for Superficial Bladder Cancer Jian Gu,1 Hua Zhao,1 Colin P. Dinney,2 Yong Zhu,3 fewer putative high-risk alleles as the reference group, Dan Leibovici,2 Carlos E. Bermejo,2 individuals with six to seven risk alleles and individuals with eight or more risk alleles had higher recurrence risks, with H. Barton Grossman,2 and Xifeng Wu1 hazard ratios of 0.92 (0.54-1.57) and 2.53 (1.48-4.30), 1 2 Departments of Epidemiology and Urology, The University of Texas respectively (P for trend < 0.001). There was also a M.D. Anderson Cancer Center, Houston, Texas, and 3Department of Epidemiology and Public Health, Yale University, New Haven, significant trend for shorter recurrence-free survival time Connecticut with increasing number of variant alleles (log rank test, P = 0.0007). When we stratified the patients according to intravesical Bacillus Calmette-Guerin treatment, we found a ABSTRACT significant trend for shorter recurrence-free survival time in Purpose: Interindividual differences in DNA repair patients with variant alleles of XPA or ERCC6 polymor- capacity not only modify individual susceptibility to carci- phisms who received Bacillus Calmette-Guerin treatment nogenesis, but also affect individual response to cancer (log rank test, P = 0.078 and 0.022, respectively). There were treatment. Nucleotide excision repair (NER) is one of the no significant individual or joint associations between these major DNA repair pathways in mammalian cells involved in polymorphisms and progression. the removal of a wide variety of DNA lesions. Polymorphisms Conclusions: These data suggest that interindividual in NER genes may influence DNA repair capacity and affect differences in DNA repair capacity may have an important clinical outcome of bladder cancer treatment. impact on superficial bladder cancer recurrence. A pathway- Experimental Design: To test the influence of NER gene based approach is preferred to study the effects of individual polymorphisms on superficial bladder cancer outcome polymorphism on clinical outcomes. (recurrence and progression), we conducted a follow-up study of 288 patients with superficial bladder cancer. INTRODUCTION Median follow-up among patients who were recurrence- Bladder cancer is the fifth most commonly diagnosed free at the end of observation was 21.7 months from malignancy in the United States, with more than 55,300 new diagnosis. The specific polymorphic loci examined include cases diagnosed in 2004 (1). Superficial bladder cancer accounts XPA [A/G at 5V untranslated region (UTR)], XPC (poly AT, for >85% of newly diagnosed cases. These cases comprise a Ala499Val, Lys939Gln), XPD (Asp312Asn, Lys751Gln), XPG heterogeneous group of tumors whose individual prognoses are (His1104Asp), ERCC 1 (G/T at 3V UTR), and ERCC6 difficult to predict (2). Nevertheless, following transurethral (Met1097Val, Arg1230Pro). resection, tumor recurrence rate is about 70%, and 10% to 15% of Results: The ERCC6 (Met1097Val) polymorphism had a such recurrences may be associated with progression to more significant impact on recurrence: carriers of at least one invasive forms of cancer (3, 4). Clinical and pathologic variant allele (Val) had a significantly higher recurrence risk prediction variables of disease recurrence have been extensively than carriers of the wild-type allele (Met/Met; hazard ratio, studied. In a patient cohort of 1,529 patients, tumor size, number 1.54; 95% confidence interval, 1.02-2.33). There were no of tumors, and presence of carcinoma in situ have been correlated overall statistically significant differences in the distributions with disease recurrence (5). Administration of intravesical Bacille of the other polymorphisms between patients with and Calmette-Guerin (BCG) has been found to significantly reduce without recurrence. However, when we combined these the risk of recurrence and progression. However, the response variant genotypes, there was a significant trend for an rate for BCG treatment is only 60% to 70%, and about one-third increased recurrence risk with an increasing number of of responders develop recurrence and progression (6, 7). A putative high-risk alleles. Using individuals with five or number of pathologic and molecular markers have been studied as potential predictors of outcome in bladder cancer. Mutant cell cycle and proliferative markers, including Ki-67, cytokeratin 20 Received 6/4/04; revised 1/7/05; accepted 1/13/05. and 34h, and growth factors, such as epidermal growth factor, Grant support: National Cancer Institute grants CA 74880, CA 85576 vascular endothelial growth factor, and fibroblast growth factor (X. Wu), CA 91846 (C. Dinney and X. Wu), and CA 86390 (M. Spitz). receptor-3, have been found to influence recurrence. p53, p21, The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked RB, cadherins cathepsins, metalloproteinases, BCL-2, cyto- advertisement in accordance with 18 U.S.C. Section 1734 solely to keratins, and fibroblast growth factor receptor-3 have been found indicate this fact. to be predictors of tumor progression (8). Requests for reprints: Xifeng Wu, Department of Epidemiology, Unit A possible explanation for the unpredictability of the clinical 1340, The University of Texas MD Anderson Cancer Center, 1155 Pressler Boulevard, Houston, TX 77030. Phone: 713-745-2485; Fax: course of superficial bladder cancer may be related to the fact that 713-792-4657; E-mail: [email protected]. host genetic differences may render some individuals at higher D2005 American Association for Cancer Research. risk than others. Functional polymorphisms may account for Downloaded from clincancerres.aacrjournals.org on September 30, 2021. © 2005 American Association for Cancer Research. Clinical Cancer Research 1409 phenotypic differences that lead to enhanced cancer risk. The Genotyping. Genomic DNA was first isolated from associations between genetic polymorphisms and cancer risk have peripheral blood lymphocytes by proteinase K digestion been extensively reported; however, few studies have focused on followed by isopropanol extraction and ethanol precipitation; polymorphisms as predictors of specific clinical events. the sample was then coded and then subjected to genotyping. One of the pathways for carcinogenesis is related to DNA The specific polymorphic loci examined include XPA (A/G at damage and repair. DNA repair systems are essential for 5V UTR, rs1800975), XPC (poly AT, Ala499Val, Lys939Gln), maintaining genomic integrity. The ability to monitor and repair XPD (Asp312Asn, Lys751Gln), XPG (His1104Asp), ERCC1 (G/T carcinogen-induced DNA damage is an important determinant of at 3V UTR, rs3212986), and ERCC6 (Met1097Val, Arg1230Pro). susceptibility to carcinogenesis. There is considerable evidence Most of the polymorphisms, except for XPA, XPC (poly AT in suggesting that reduced DNA repair capacity may play a role in intron 11), and XPD (Asp312Asn), were determined using cigarette smoking–related cancer risk (9, 10). Interestingly, in TaqMan real-time PCR. The primer and probe sequences, terms of cancer recurrence and survival, efficient DNA repair which are available upon request, were either obtained from capacity is not always a favorable prediction factor. Catto et al. National Cancer Institute’s SNP500 database or designed using (11) reported that reduced expression of two mismatch repair Primer Express Software. The probes were labeled fluorescently genes, hMLH1 and hMSH2, was associated with fewer with either FAM or VIC on the 5V end and a nonfluorescent recurrences of superficial bladder cancer. In addition, Bosken minor groove binder quencher on the 3V end (Applied et al. (12) found that effective host DNA repair capacity was Biosystems, Foster City, CA). Typical amplification mixes (5 associated with poorer survival in patients with non–small cell AL) contained sample DNA (5 ng), 1Â TaqMan buffer A, 200 lung cancer who were treated with chemotherapy. Am deoxynucleotide triphosphates, 5 mmol MgCl2, 0.65 units Nucleotide excision repair (NER), one of the major DNA of AmpliTaq Gold, 900 nmol/L each primer, and 200 nmol/L repair pathways in mammalian cells, is involved in the removal of each probe. The thermal cycling conditions consisted of 1 cycle a wide variety of DNA lesions, including bulky carcinogen for 10 minutes at 95jC, 40 cycles for 15 seconds at 95jC, adducts resulting from tobacco exposure. All key NER factors and 1 minute at 60jC. SDS version 2.1 software (Applied have been cloned, and the core of the ‘‘cut-and-paste’’ reaction Biosystems) was used to analyze end-point fluorescence. Water has been reconstituted in vitro (13). Most NER genes are control, internal controls, and previously genotyped samples polymorphic, and some of the polymorphisms have been were included in each plate to ensure accuracy of genotyping. extensively studied in terms of their associations with cancer risk Genotyping for XPA, XPC (poly AT in intron 11), and XPD as well as clinical outcomes in specific cancer types (14–17). (Asp312Asn) were done as described previously using PCR- However, most studies have used a candidate gene approach, RFLP (14–16). investigating one single nucleotide polymorphism (SNP) in a Statistical Analyses. v2 analyses and Fisher’s exact test single gene. In the current study, we applied a pathway-based were used to assess
Load more

Recommended publications
  • Deficiency in the DNA Repair Protein ERCC1 Triggers a Link Between Senescence and Apoptosis in Human Fibroblasts and Mouse Skin
    Lawrence Berkeley National Laboratory Recent Work Title Deficiency in the DNA repair protein ERCC1 triggers a link between senescence and apoptosis in human fibroblasts and mouse skin. Permalink https://escholarship.org/uc/item/73j1s4d1 Journal Aging cell, 19(3) ISSN 1474-9718 Authors Kim, Dong Eun Dollé, Martijn ET Vermeij, Wilbert P et al. Publication Date 2020-03-01 DOI 10.1111/acel.13072 Peer reviewed eScholarship.org Powered by the California Digital Library University of California Received: 10 June 2019 | Revised: 7 October 2019 | Accepted: 30 October 2019 DOI: 10.1111/acel.13072 ORIGINAL ARTICLE Deficiency in the DNA repair protein ERCC1 triggers a link between senescence and apoptosis in human fibroblasts and mouse skin Dong Eun Kim1 | Martijn E. T. Dollé2 | Wilbert P. Vermeij3,4 | Akos Gyenis5 | Katharina Vogel5 | Jan H. J. Hoeijmakers3,4,5 | Christopher D. Wiley1 | Albert R. Davalos1 | Paul Hasty6 | Pierre-Yves Desprez1 | Judith Campisi1,7 1Buck Institute for Research on Aging, Novato, CA, USA Abstract 2Centre for Health Protection Research, ERCC1 (excision repair cross complementing-group 1) is a mammalian endonuclease National Institute of Public Health and that incises the damaged strand of DNA during nucleotide excision repair and inter- the Environment (RIVM), Bilthoven, The −/Δ Netherlands strand cross-link repair. Ercc1 mice, carrying one null and one hypomorphic Ercc1 3Department of Molecular Genetics, allele, have been widely used to study aging due to accelerated aging phenotypes Erasmus University Medical Center, −/Δ Rotterdam, The Netherlands in numerous organs and their shortened lifespan. Ercc1 mice display combined 4Princess Máxima Center for Pediatric features of human progeroid and cancer-prone syndromes.
    [Show full text]
  • Open Full Page
    CCR PEDIATRIC ONCOLOGY SERIES CCR Pediatric Oncology Series Recommendations for Childhood Cancer Screening and Surveillance in DNA Repair Disorders Michael F. Walsh1, Vivian Y. Chang2, Wendy K. Kohlmann3, Hamish S. Scott4, Christopher Cunniff5, Franck Bourdeaut6, Jan J. Molenaar7, Christopher C. Porter8, John T. Sandlund9, Sharon E. Plon10, Lisa L. Wang10, and Sharon A. Savage11 Abstract DNA repair syndromes are heterogeneous disorders caused by around the world to discuss and develop cancer surveillance pathogenic variants in genes encoding proteins key in DNA guidelines for children with cancer-prone disorders. Herein, replication and/or the cellular response to DNA damage. The we focus on the more common of the rare DNA repair dis- majority of these syndromes are inherited in an autosomal- orders: ataxia telangiectasia, Bloom syndrome, Fanconi ane- recessive manner, but autosomal-dominant and X-linked reces- mia, dyskeratosis congenita, Nijmegen breakage syndrome, sive disorders also exist. The clinical features of patients with DNA Rothmund–Thomson syndrome, and Xeroderma pigmento- repair syndromes are highly varied and dependent on the under- sum. Dedicated syndrome registries and a combination of lying genetic cause. Notably, all patients have elevated risks of basic science and clinical research have led to important in- syndrome-associated cancers, and many of these cancers present sights into the underlying biology of these disorders. Given the in childhood. Although it is clear that the risk of cancer is rarity of these disorders, it is recommended that centralized increased, there are limited data defining the true incidence of centers of excellence be involved directly or through consulta- cancer and almost no evidence-based approaches to cancer tion in caring for patients with heritable DNA repair syn- surveillance in patients with DNA repair disorders.
    [Show full text]
  • DNA Repair with Its Consequences (E.G
    Cell Science at a Glance 515 DNA repair with its consequences (e.g. tolerance and pathways each require a number of apoptosis) as well as direct correction of proteins. By contrast, O-alkylated bases, Oliver Fleck* and Olaf Nielsen* the damage by DNA repair mechanisms, such as O6-methylguanine can be Department of Genetics, Institute of Molecular which may require activation of repaired by the action of a single protein, Biology, University of Copenhagen, Øster checkpoint pathways. There are various O6-methylguanine-DNA Farimagsgade 2A, DK-1353 Copenhagen K, Denmark forms of DNA damage, such as base methyltransferase (MGMT). MGMT *Authors for correspondence (e-mail: modifications, strand breaks, crosslinks removes the alkyl group in a suicide fl[email protected]; [email protected]) and mismatches. There are also reaction by transfer to one of its cysteine numerous DNA repair pathways. Each residues. Photolyases are able to split Journal of Cell Science 117, 515-517 repair pathway is directed to specific Published by The Company of Biologists 2004 covalent bonds of pyrimidine dimers doi:10.1242/jcs.00952 types of damage, and a given type of produced by UV radiation. They bind to damage can be targeted by several a UV lesion in a light-independent Organisms are permanently exposed to pathways. Major DNA repair pathways process, but require light (350-450 nm) endogenous and exogenous agents that are mismatch repair (MMR), nucleotide as an energy source for repair. Another damage DNA. If not repaired, such excision repair (NER), base excision NER-independent pathway that can damage can result in mutations, diseases repair (BER), homologous recombi- remove UV-induced damage, UVER, is and cell death.
    [Show full text]
  • Curriculum Vitae
    CURRICULUM VITAE NAME: Patricia Lynn Opresko BUSINESS ADDRESS: University of Pittsburgh Graduate School of Public Health Department of Environmental and UPMC Hillman Cancer Center 5117 Centre Avenue, Suite 2.6a Pittsburgh, PA15213-1863 Phone: 412-623-7764 Fax: 412-623-7761 E-mail: [email protected] EDUCATION AND TRAINING Undergraduate 1990 - 1994 DeSales University B.S., 1994 Chemistry and Center Valley, PA Biology Graduate 1994 - 2000 Pennsylvania State Ph.D., 2000 Biochemistry and University, College of Molecular Biology Medicine, Hershey, PA Post-Graduate 3/2000 - 5/2000 Pennsylvania State Postdoctoral Dr. Kristin Eckert, University, College of Fellow Mutagenesis and Medicine, Jake Gittlen Cancer etiology Cancer Research Institute Hershey, PA 2000-2005 National Institute on IRTA Postdoctoral Dr. Vilhelm Bohr Aging, National Fellow Molecular Institutes of Health, Gerontology and Baltimore, MD DNA Repair 1 APPOINTMENTS AND POSITIONS Academic 8/1/2018 – Co-leader Genome Stability Program, UPMC present Hillman Cancer Center 5/1/2018- Tenured Professor Pharmacology and Chemical Biology, present School of Medicine, University of Pittsburgh, Pittsburgh, PA 2/1/2018- Tenured Professor Environmental and Occupational Health, present Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 2014 – Tenured Associate Environmental and Occupational Health, 1/31/2018 Professor Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 2005 - 2014 Assistant Professor Environmental and Occupational Health, Graduate School
    [Show full text]
  • DNA Proofreading and Repair
    DNA proofreading and repair Mechanisms to correct errors during DNA replication and to repair DNA damage over the cell's lifetime. Key points: Cells have a variety of mechanisms to prevent mutations, or permanent changes in DNA sequence. During DNA synthesis, most DNA polymerases "check their work," fixing the majority of mispaired bases in a process called proofreading. Immediately after DNA synthesis, any remaining mispaired bases can be detected and replaced in a process called mismatch repair. If DNA gets damaged, it can be repaired by various mechanisms, including chemical reversal, excision repair, and double-stranded break repair. Introduction What does DNA have to do with cancer? Cancer occurs when cells divide in an uncontrolled way, ignoring normal "stop" signals and producing a tumor. This bad behavior is caused by accumulated mutations, or permanent sequence changes in the cells' DNA. Replication errors and DNA damage are actually happening in the cells of our bodies all the time. In most cases, however, they don’t cause cancer, or even mutations. That’s because they are usually detected and fixed by DNA proofreading and repair mechanisms. Or, if the damage cannot be fixed, the cell will undergo programmed cell death (apoptosis) to avoid passing on the faulty DNA. Mutations happen, and get passed on to daughter cells, only when these mechanisms fail. Cancer, in turn, develops only when multiple mutations in division-related genes accumulate in the same cell. In this article, we’ll take a closer look at the mechanisms used by cells to correct replication errors and fix DNA damage, including: Proofreading, which corrects errors during DNA replication Mismatch repair, which fixes mispaired bases right after DNA replication DNA damage repair pathways, which detect and correct damage throughout the cell cycle Proofreading DNA polymerases are the enzymes that build DNA in cells.
    [Show full text]
  • Haplotype Patterns in Cancer-Related Genes with Long-Range Linkage Disequilibrium: No Evidence of Association with Breast Cancer Or Positive Selection
    European Journal of Human Genetics (2008) 16, 252–260 & 2008 Nature Publishing Group All rights reserved 1018-4813/08 $30.00 www.nature.com/ejhg ARTICLE Haplotype patterns in cancer-related genes with long-range linkage disequilibrium: no evidence of association with breast cancer or positive selection Gloria Ribas*,1, Roger L Milne2, Anna Gonzalez-Neira2 and Javier Benı´tez1,2 1Human Genetics Group, Human Cancer Genetics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain; 2National Genotyping Centre (CeGen), Human Cancer Genetics Programme, Spanish National Cancer Centre (CNIO), Madrid, Spain The average length of linkage disequilibrium (LD) blocks in European populations is about 22 kb. In this study, we have selected 20 genes with LD blocks larger than 60 kb (with a median length of 88 kb) from a total of 121 cancer-related genes. We observed limited haplotype diversity, with an average of three haplotypes per gene accounting for more than 90% of the diversity, two of these being a Yin–Yang pair in 95% of the LD blocks. The mean frequency of the most common haplotype in the Spanish population was just below 50%, similar to those for the HapMap CEU and African samples, but lower than the 60% observed in Asian samples. Genes involved in the regulation of nucleobases and nucleic acid metabolism were overrepresented among these 20 genes with long LD blocks (eight genes ATM, BRCA1, BRCA2, ERCC6, MLH1, MSH3, RAD54B and XRCC4) relative to the other 101 cancer-related genes studied (P ¼ 1.23 Â 10À6). The ancestral haplotype was observed at a frequency greater than 3 in 67% of the genes either in the Spanish or one of the HapMap sampled populations.
    [Show full text]
  • Hyper Telomere Recombination Accelerates Replicative Senescence and May Promote Premature Aging
    Hyper telomere recombination accelerates replicative senescence and may promote premature aging R. Tanner Hagelstroma,b, Krastan B. Blagoevc,d, Laura J. Niedernhofere, Edwin H. Goodwinf, and Susan M. Baileya,1 aDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, CO 80523-1618; bPharmaceutical Genomics Division, Translational Genomics Research Institute, Phoenix, AZ 85004; cNational Science Foundation, Arlington, VA 22230; dDepartment of Physics Cavendish Laboratory, Cambridge University, Cambridge CB3 0HE, United Kingdom; eDepartment of Microbiology and Molecular Genetics, University of Pittsburgh, School of Medicine and Cancer Institute, Pittsburgh, PA 15261; and fKromaTiD Inc., Fort Collins, CO 80524 Edited* by José N. Onuchic, University of California San Diego, La Jolla, CA, and approved August 3, 2010 (received for review May 7, 2010) Werner syndrome and Bloom syndrome result from defects in the cell-cycle arrest known as senescence (12). Most human tissues lack RecQ helicases Werner (WRN) and Bloom (BLM), respectively, and sufficient telomerase activity to maintain telomere length through- display premature aging phenotypes. Similarly, XFE progeroid out life, limiting cell division potential. The majority of cancers syndrome results from defects in the ERCC1-XPF DNA repair endo- circumvent this tumor-suppressor mechanism by reactivating telo- nuclease. To gain insight into the origin of cellular senescence and merase (13), thus removing telomere shortening as a barrier to human aging, we analyzed the dependence of sister chromatid continuous proliferation. In some situations, a recombination- exchange (SCE) frequencies on location [i.e., genomic (G-SCE) vs. telo- based mechanism known as “alternative lengthening of telomeres” meric (T-SCE) DNA] in primary human fibroblasts deficient in WRN, (ALT) maintains telomere length in the absence of telomerase (14).
    [Show full text]
  • The Consequences of Rad51 Overexpression for Normal and Tumor Cells
    dna repair 7 (2008) 686–693 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/dnarepair Mini review The consequences of Rad51 overexpression for normal and tumor cells Hannah L. Klein ∗ Department of Biochemistry, New York University School of Medicine, NYU Medical Center, 550 First Avenue, New York, NY 10016, United States article info abstract Article history: The Rad51 recombinase is an essential factor for homologous recombination and the Received 11 December 2007 repair of DNA double strand breaks, binding transiently to both single stranded and double Accepted 12 December 2007 stranded DNA during the recombination reaction. The use of a homologous recombination Published on line 1 February 2008 mechanism to repair DNA damage is controlled at several levels, including the binding of Rad51 to single stranded DNA to form the Rad51 nucleofilament, which is controlled through Keywords: the action of DNA helicases that can counteract nucleofilament formation. Overexpression Rad51 protein of Rad51 in different organisms and cell types has a wide assortment of consequences, rang- Overexpression of Rad51 ing from increased homologous recombination and increased resistance to DNA damaging Genomic instability agents to disruption of the cell cycle and apoptotic cell death. Rad51 expression is increased Tumor cell drug resistance in p53-negative cells, and since p53 is often mutated in tumor cells, there is a tendency for Homologous recombination Rad51 to be overexpressed in tumor cells, leading to increased resistance to DNA damage Gene targeting and drugs used in chemotherapies. As cells with increased Rad51 levels are more resis- tant to DNA damage, there is a selection for tumor cells to have higher Rad51 levels.
    [Show full text]
  • Defective DNA Repair and Chromatin Organization in Patients with Quiescent Systemic Lupus Erythematosus Vassilis L
    Souliotis et al. Arthritis Research & Therapy (2016) 18:182 DOI 10.1186/s13075-016-1081-3 RESEARCH ARTICLE Open Access Defective DNA repair and chromatin organization in patients with quiescent systemic lupus erythematosus Vassilis L. Souliotis1,2*, Konstantinos Vougas3, Vassilis G. Gorgoulis3,4 and Petros P. Sfikakis2 Abstract Background: Excessive autoantibody production characterizing systemic lupus erythematosus (SLE) occurs irrespective of the disease’s clinical status and is linked to increased lymphocyte apoptosis. Herein, we tested the hypothesis that defective DNA damage repair contributes to increased apoptosis in SLE. Methods: We evaluated nucleotide excision repair at the N-ras locus, DNA double-strand breaks repair and apoptosis rates in peripheral blood mononuclear cells from anti-dsDNA autoantibody-positive patients (six with quiescent disease and six with proliferative nephritis) and matched healthy controls following ex vivo treatment with melphalan. Chromatin organization and expression levels of DNA repair- and apoptosis-associated genes were also studied in quiescent SLE. Results: Defective nucleotide excision repair and DNA double-strand breaks repair were found in SLE, with lupus nephritis patients showing higher DNA damage levels than those with quiescent disease. Melphalan-induced apoptosis rates were higher in SLE than control cells and correlated inversely with DNA repair efficiency. Chromatin at the N-ras locus was more condensed in SLE than controls, while treatment with the histone deacetylase inhibitor vorinostat resulted in hyperacetylation of histone H4, chromatin decondensation, amelioration of DNA repair efficiency and decreased apoptosis. Accordingly, genes involved in DNA damage repair and signaling pathways, such as DDB1, ERCC2, XPA, XPC, MRE11A, RAD50, PARP1, MLH1, MLH3, and ATM were significantly underexpressed in SLE versus controls, whereas PPP1R15A, BARD1 and BBC3 genes implicated in apoptosis were significantly overexpressed.
    [Show full text]
  • Potentially Functional Single Nucleotide Polymorphisms in the Core Nucleotide Excision Repair Genes and Risk of Squamous Cell Carcinoma of the Head and Neck
    1633 Potentially Functional Single Nucleotide Polymorphisms in the Core Nucleotide Excision Repair Genes and Risk of Squamous Cell Carcinoma of the Head and Neck Jiaze An,1 Zhensheng Liu,1 Zhibin Hu,1 Guojun Li,1 Li-E Wang,1 Erich M. Sturgis,1,2 AdelK. El-Naggar, 2,3 Margaret R. Spitz,1 and Qingyi Wei1 Departments of 1Epidemiology, 2Head and Neck Surgery, and 3Pathology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas Abstract Susceptibility to cancer has been associated with DNA SCCHN risk (adjusted odds ratio, 1.65; 95% confidence repair capacity, a global reflection of all functional variants, interval, 1.16-2.36). In analysis of the joint effects, the most of which are relatively rare. Among the 1,098 single number of observed risk genotypes was associated with nucleotide polymorphisms (SNP) identified in the eight SCCHN risk in a dose-response manner (P for trend = 0.017) core nucleotide excision repair genes, only a few are and those who carried four or more risk genotypes exhibited common nonsynonymous or regulatory SNPs that are a borderline significant 1.23-fold increased SCCHN risk potentially functional. We tested the hypothesis that seven (adjusted odds ratio, 1.23; 95% confidence interval, 0.99-1.53). selected common nonsynonymous and regulatory variants In the stratified analysis, the dichotomized combined effect in the nucleotide excision repair core genes are associated of the seven SNPs was slightly more evident among older with risk of squamous cell carcinoma of the head and neck subjects, women, and laryngeal cancer. These findings (SCCHN) in a hospital-based, case-control study of 829 suggest that these potentially functional SNPs may collec- SCCHN cases and 854 cancer-free controls.
    [Show full text]
  • Can Synthetic Lethality Approach Be Used with DNA Repair Genes for Primary and Secondary MDS?
    Medical Oncology (2019) 36:99 https://doi.org/10.1007/s12032-019-1324-7 ORIGINAL PAPER Can synthetic lethality approach be used with DNA repair genes for primary and secondary MDS? Howard Lopes Ribeiro Junior1,2 · Roberta Taiane Germano de Oliveira1,2 · Daniela de Paula Borges1,2 · Marília Braga Costa1,2 · Izabelle Rocha Farias1,2 · Antônio Wesley Araújo dos Santos1,2 · Silvia Maria Meira Magalhães1,2 · Ronald Feitosa Pinheiro1,2,3 Received: 5 August 2019 / Accepted: 15 October 2019 / Published online: 30 October 2019 © Springer Science+Business Media, LLC, part of Springer Nature 2019 Abstract Cancer-specifc defects in DNA repair pathways create the opportunity to employ synthetic lethality approach. Recently, GEMA (gene expression and mutation analysis) approach detected insufcient expression of BRCA or NHEJ (non-homol- ogous end joining) to predict PARP inhibitors response. We evaluated a possible role of DNA repair pathways using gene expression of single-strand break (XPA, XPC, XPG/ERCC5, CSA/ERCC8, and CSB/ERCC6) and double-strand break (ATM, BRCA1, BRCA2, RAD51, XRCC5, XRCC6, LIG4) in 92 patients with myelodysplastic syndrome (73 de novo, 9 therapy- related (t-MDS). Therapy-related MDS (t-MDS) demonstrated a signifcant downregulation of axis BRCA1-BRCA2-RAD51 comparing to normal controls (p = 0.048, p = 0.001, p = 0.001). XRCC6 showed signifcantly low expression in de novo MDS comparing to controls (p = 0.039) and for patients who presented chromosomal abnormalities (p = 0.047). Downregula- tion of LIG4 was consistently associated with poor prognostic markers in de novo MDS (hemoglobin < 8 g/dL (p = 0.040), neutrophils < 800/mm3 (p < 0.001), patients with excess of blasts (p = 0.001), very high (p = 0.002)/high IPSS-R (p = 0.043) and AML transformation (p < 0.001).
    [Show full text]
  • Muts Homologue 2 and the Long-Term Benefit of Adjuvant Chemotherapy in Lung Cancer
    Published OnlineFirst February 9, 2010; DOI: 10.1158/1078-0432.CCR-09-2204 Published Online First on February 9, 2010 as 10.1158/1078-0432.CCR-09-2204 Clinical Imaging, Diagnosis, Prognosis Cancer Research MutS Homologue 2 and the Long-term Benefit of Adjuvant Chemotherapy in Lung Cancer Nermine S. Kamal1, Jean-Charles Soria1,2, Jean Mendiboure3, David Planchard1, Ken A. Olaussen1, Vanessa Rousseau3, Helmut Popper5, Robert Pirker6, Pascale Bertrand7, Ariane Dunant3, Thierry Le Chevalier4, Martin Filipits6, and Pierre Fouret1,8 for the International Adjuvant Lung Trial-Bio investigators Abstract Purpose: We sought to determine the long-term (median follow-up, 7.5 years) predictive power of human MutS homologue 2 (MSH2) immunohistochemical expression in patients who enrolled in the International Adjuvant Lung Trial. Experimental design: We tested the interaction between MSH2 and the allocated treatment (chemo- therapy versus observation) in a Cox model adjusted on clinicopathologic variables. The significance level was set at 0.01. Results: MSH2 levels were low in 257 (38%) and high in 416 (62%) tumors. The benefit from che- motherapy was likely different according to MSH2 (interaction test, P = 0.06): there was a trend for che- motherapy to prolong overall survival when MSH2 was low [hazard ratio (HR), 0.76; 95% confidence interval (95% CI), 0.59-0.97; P = 0.03], but not when MSH2 was high (HR, 1.12; 95% CI, 0.81-1.55; P = 0.48). In the control arm, the HR was 0.66 (95% CI, 0.49-0.90; P = 0.01) when MSH2 was high. When combining MSH2 with excision repair cross-complementing group 1 (ERCC1) into four subgroups, the benefit of chemotherapy decreased with the number of markers expressed at high levels (P = 0.01).
    [Show full text]